3月5日下午，北京積水潭醫(yī)院鄭州醫(yī)院（鄭州市中心醫(yī)院）成功舉辦LVA手術(shù)治療阿爾茨海默病中德研討會(huì)。會(huì)議由醫(yī)院黨委書(shū)記馬西文教授以全英語(yǔ)致歡迎辭，由鄭州大學(xué)創(chuàng)傷與代謝研究院執(zhí)行院長(zhǎng)葉建平教授主持。神經(jīng)內(nèi)科、老年醫(yī)學(xué)科、顯微外科、檢驗(yàn)科、病理科、影像科、麻醉科等多個(gè)相關(guān)學(xué)科團(tuán)隊(duì)共約80人參會(huì)，現(xiàn)場(chǎng)學(xué)術(shù)氛圍濃厚。研討會(huì)特別邀請(qǐng)到德國(guó)哥廷根大學(xué)醫(yī)療中心精神病學(xué)與心理治療科主任Wiltfang教授，他圍繞阿爾茨海默病的發(fā)病機(jī)制、診斷方法、疾病分期及生物標(biāo)志物在早期篩查和預(yù)防性治療中的應(yīng)用進(jìn)行了深入講解。Wiltfang教授指出，阿爾茨海默病的病理變化早在癥狀出現(xiàn)前15 - 20年就已開(kāi)始，主要表現(xiàn)為β淀粉樣蛋白（Aβ）沉積和Tau蛋白異常。當(dāng)前PET掃描和腦脊液（CSF）檢測(cè)雖然準(zhǔn)確，但因費(fèi)用高或具有侵入性，難以在大規(guī)模篩查中推廣。因此，血漿生物標(biāo)志物檢測(cè)因其便捷、微創(chuàng)、低成本的優(yōu)勢(shì)，成為全球研究的熱點(diǎn)。他詳細(xì)介紹了其團(tuán)隊(duì)自主研發(fā)的Aβ-IP-IA & Tau-IP-IA血漿檢測(cè)技術(shù)，這一方法結(jié)合了免疫沉淀（IP）和高靈敏度免疫檢測(cè)（IA），可精準(zhǔn)檢測(cè)Aβ1-42/1-40比值和p-Tau217水平。在臨床研究中，該方法對(duì)早期阿爾茨海默病高風(fēng)險(xiǎn)個(gè)體的識(shí)別準(zhǔn)確率高達(dá)91%，并可在癥狀出現(xiàn)15年前檢測(cè)到病變。此外，研究團(tuán)隊(duì)提出了AT-RATIO這一全新血漿診斷指標(biāo)，相較于單一生物標(biāo)志物檢測(cè)，該指標(biāo)可進(jìn)一步提高阿爾茨海默病的早期篩查精準(zhǔn)度。Wiltfang教授強(qiáng)調(diào)，早期診斷對(duì)于阿爾茨海默病的干預(yù)至關(guān)重要。研究發(fā)現(xiàn)，在MCI階段（輕度認(rèn)知障礙）前即啟動(dòng)抗Aβ治療，不僅可顯著提高療效，還能減少副作用。因此，血漿生物標(biāo)志物檢測(cè)不僅可以用于大規(guī)模篩查，還能為個(gè)體化治療提供重要指導(dǎo)，優(yōu)化抗Aβ藥物的使用策略，為阿爾茨海默病的早期干預(yù)和預(yù)防性治療帶來(lái)新的可能。隨后，葉建平教授全英文分享了醫(yī)院認(rèn)知中心的診療現(xiàn)狀，并圍繞脂代謝紊亂與阿爾茨海默病的關(guān)系及LVA手術(shù)治療阿爾茨海默病的機(jī)制與療效展開(kāi)講解。Wiltfang教授對(duì)這一研究方向表現(xiàn)出極大興趣，雙方研究重點(diǎn)高度契合，討論熱烈，會(huì)議超時(shí)20分鐘仍意猶未盡，并約定未來(lái)繼續(xù)深化交流，共同推動(dòng)阿爾茨海默病的早期診斷與創(chuàng)新治療。此次研討會(huì)不僅促進(jìn)了中德雙方的深入合作，也為阿爾茨海默病的早期篩查和創(chuàng)新治療提供了新思路。期待未來(lái)更多國(guó)際交流，共同推進(jìn)這一全球難題的解決！

On the afternoon of March 5, the Sino-German Webinar on LVA Treating Alzheimer’s Disease (AD) was successfully held at Beijing Jishuitan Hospital, Zhengzhou Hospital (Zhengzhou Central Hospital).The event was officially opened with a welcome speech in English by Prof. MA Xiwen, Party Secretary of the hospital, and was chaired by Prof. YE Jianping, Executive Director of the Institute of Trauma and Metabolism at Zhengzhou University. The webinar attracted about 80 participants from multiple departments, including neurology, geriatric medicine, microsurgery, laboratory medicine, pathology, radiology, and anesthesiology, fostering a strong academic atmosphere. The webinar featured Prof. Wiltfang, Director of the Department of Psychiatry and Psychotherapy at the University Medical Center G?ttingen, Germany. He delivered an in-depth lecture on the validated core neuropathology of Alzheimer’s disease, the current clinical model of AD and the CSF and blood based early and differential diagnosis of AD, with a focus on the clinical relevance of blood based preclinical diagnosis of AD in view of first preventive treatment options. Prof. Wiltfang highlighted that pathological changes in Alzheimer’s disease begin 15-20 years before clinical symptoms appear, primarily characterized by deposits of the β-amyloid peptide (Aβ) and the flame-shaped neurofibrillary tangles of the microtubule binding protein tau. Although cerebrospinal based neurochemical dementia diagnostics (CSF-NDD) and Amyloid-PET offer high diagnostic accuracy, their high cost and invasiveness limit the feasibility for large-scale screening. As a result, Blood based neurochemical dementia diagnostics (Blood-NDD) - with their advantages of convenience, minimal invasiveness, and low cost - have become a global research hotspot. Prof. Wiltfang introduced the IP-IA developed by his team, a novel assay platform combining initial robotic immunoprecipitation (IP) and second step commercially available high throughput capable immunoassay technologies (IA) to precisely measure Aβ1-42/Aβ1-40 ratio and p-Tau217 levels. Clinical studies have shown that this method can identify high-risk individuals with 91% accuracy and detect pathological changes up to 15 years before symptom onset. Additionally, his team proposed a new AT-RATIO offering a single cut-off value: Aβ1-40/1-42 * phospho-Tau217, which improves early screening accuracy compared to single-biomarker detection. Prof. Wiltfang emphasized that early diagnosis is crucial for effective intervention in Alzheimer’s disease. Research shows that initiating reducing-Aβ therapy before the Mild Cognitive Impairment (MCI) stage not only significantly enhances treatment efficacy but also reduces side effects. Blood plasma assays not only facilitates large-scale screening but also provides critical guidance for personalized treatment, helping optimize reducing-Aβ pharmacological strategies and offering new possibilities for early intervention and preventive therapy.Following this, Prof. YE Jianping delivered an English presentation on the hospital’s cognitive center and elaborated on the relationship between lipid metabolism disorders and Alzheimer’s disease, as well as the mechanism and efficacy of LVA surgery for AD treatment. Prof. Wiltfang expressed great interest in this research direction, as both teams share highly aligned research priorities. The discussion was so engaging that the meeting extended 20 minutes beyond schedule, and both sides agreed to further strengthen future collaborations to further develop early diagnosis and innovative treatments for Alzheimer’s disease. The webianr not only deepened Sino-German collaboration but also provided new perspectives on early screening and innovative treatment strategies for Alzheimer’s disease. We look forward to more international exchanges in the future to jointly navigate this global challenge.